Sunil Singhania's Abakkus Small Cap Fund keeps buying Q-Line Biotech after a near-100% gain
Sunil Singhania's Abakkus Small Cap Fund was the single largest anchor investor in India's largest-ever SME IPO anchor book at the time — and five months later, it has increased that position by nearly 70% rather than trimming it after a near-100% gain.
Q-Line Biotech Ltd - Share price: ₹668.45 (Sept 25, 2026 close — check the live price) - Market cap: ₹1,559 crore - P/E: ~27.6x, versus a peer-group median of ~36.3x and its closest listed peer, Molbio Diagnostics, at ~66.1x — Q-Line trades at a lower P/E than this selected peer group's median
The anchor bet, then the follow-through
Q-Line Biotech is listed on NSE Emerge (NSE-SME), not the mainboard — it listed on May 29, 2026, after a ₹326-343 price band IPO. Abakkus Small Cap Fund bought in at the top of that band: 2,91,600 shares at ₹343 apiece (~₹10 crore) in the anchor round on May 20, 2026, taking 16.37% of the entire anchor book — the single largest anchor investor in a round that raised ₹61.10 crore total, reported as India's largest SME IPO anchor book at the time. Fellow anchors included Vikas Khemani's Carnelian Fund and another Abakkus-managed vehicle, Bharat Venture Opportunities Fund.
That alone would be a normal anchor allocation. What makes it notable is what happened next: rather than sitting on the anchor stake, Abakkus Small Cap Fund kept buying. Monthly portfolio disclosures show the fund held 4,93,200 shares as of August 31, 2026 — up from 2,91,600 at anchor, an increase of about 69%. As of that August 31 snapshot, the holding was worth ₹29.4 crore, 1.05% of the fund's NAV (at the September 25 closing price of ₹668.45, the same shares would be worth roughly ₹33 crore). It built this position up while the stock itself climbed from ₹343 to ₹668 (about +95%) — buying more into a position that was already working, not averaging down.
The lesson: an anchor allocation is a first bet, not the final word. A fund adding to a winning position rather than banking the gain can be read as a stronger conviction signal than the original anchor check — though it doesn't by itself prove the fund's future view of the stock, and it does mean more of the fund's money is now riding on one small, thinly-traded stock.
What Q-Line actually does
Incorporated on November 10, 2010, though the promoter family describes over 31 years of experience in diagnostics — as importers and traders of diagnostic products before the recent shift to in-house manufacturing — predating the company itself. Q-Line is a Lucknow-based in-vitro diagnostics (IVD) company — it makes the reagents (the chemical liquids that produce a blood-test result), the analyzer machines that run those tests, and the disposable supplies that go with them, sold mainly to government hospitals, community health centres, and private labs.
The business runs on a razor-blade model: some instruments are placed at low upfront cost, or under arrangements (including government programmes that fund the equipment) designed to drive subsequent reagent consumption — the machine itself isn't the profit centre, the years of recurring reagent orders that follow are. Q-Line has a cumulative installed base of 15,000-17,000 instruments since inception, and reagents alone make up about 70% of revenue.
The financial turnaround behind the stock's move
Metric FY26 FY25 Change ------------ Revenue ₹341.7 Cr ₹313.1 Cr +9% Gross margin 60.8% 53.3% +750 bps EBITDA ₹98.1 Cr ₹70.6 Cr +39% EBITDA margin 28.7% 22.5% +620 bps PAT (as reported) ₹55.7 Cr ₹19.2 Cr up sharply PAT margin 16.3% 6.1% +1,020 bps
FY25's reported PAT was depressed by extraordinary and prior-period charges, per management's own comments on the call — a company disclosure elsewhere cites an adjusted (excluding-extraordinary-items) PAT of ₹56.71 Cr versus ₹36.18 Cr, a smaller but still real jump. Either way, the direction is the same: profitability improved sharply.
The jump wasn't from selling more — revenue grew a modest 9% — it was from selling better. Manufactured (in-house) reagents grew 70% year-on-year and now make up 70% of all reagent sales, up from a business that historically just imported and resold. Management indicated on the call that manufactured reagents carry 60-65% gross margins versus roughly 50% for traded reagents and just 15-20% for instruments — company commentary, not an independently-audited breakdown, but consistent with the reported overall margin expansion. ROE stands at 25.9% and ROCE at 22.5% — both solid for a company this size.
Management's own guidance for FY27
This was Q-Line's first earnings call as a listed company, so there's no prior guidance to check it against — these are management's own targets, not independently verified forecasts:
- Revenue growth of 30-35% in FY27, driven by the newly-commissioned Unit 4 manufacturing facility in Lucknow - EBITDA margin to hold "slightly above" FY26's 28.7% - CDMO (contract manufacturing for other companies) revenue target of ₹10 crore in FY27, its first year of meaningful activity - Export revenue to grow roughly 5x, from ₹1.2 crore to around ₹6 crore, across the Middle East, Africa, and Mauritius
The real risks in the story
Three facts from the concall matter more than the headline growth numbers:
- 77% of Q-Line's revenue is billed through a single distributor in Uttar Pradesh — and management confirmed on the call that this distributor is a related party (promoter-linked), not an independent business partner. That billing concentration doesn't necessarily mean 77% of end customers are physically in UP — the distributor supplies into other states too — but the related-party structure itself is a real governance point. Management said existing corporate guarantees extended to related parties are being wound down, with no committed timeline given. - Of the 1,550 Selectra Pro M analyzers Q-Line has placed, management indicated only around 450 were active for reagent ordering at the time — a significant portion of the installed base has yet to translate into the recurring revenue the whole business model depends on. - FY26 receivable days ran around 134 days — investors should watch working capital here, since reported profit doesn't automatically translate into cash at the same pace.
Being SME-listed also means real liquidity constraints: SME stocks trade in bigger lots with thinner daily volumes than mainboard stocks, so getting in or out of a large position — like the one Abakkus has been building — can take longer and move the price more than a similar-sized mainboard trade would.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.screener.in/company/QLINE/consolidated/ - https://www.outlookbusiness.com/markets/q-line-biotech-mobilises-over-61-crore-from-anchor-investors-ipo-to-open-on-thursday - https://ipocentral.in/q-line-biotech-anchor-book-allocation/ - https://ipowatch.in/q-line-biotech-ipo-listing/